U.S. Physical Therapy Reports 13% Q3 Revenue Growth, Reaffirms EBITDA Guidance
U.S. Physical Therapy reported Q3 revenue growth of 13% to $223M, with EBITDA up 16% to $28M. The company reaffirmed its full-year EBITDA guidance of $102M-$106M. Growth was driven by increased physical therapy visits and hospital affiliations, while higher employee health benefit costs impacted margins.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance reaffirmation suggest a positive catalyst for the stock, potentially driving short‑term upside.
Market read
First‑time disclosure of solid Q3 results for a mid‑cap healthcare services company, offering a clear trading signal.
What to watch
Higher employee health benefit costs could pressure margins in future quarters.
Background
U.S. Physical Therapy Inc released its Q3 2026 earnings via an 8‑K filing, highlighting revenue growth, EBITDA expansion, and reaffirmed guidance.
Ticker impact
Q3 revenue rose 13% to $223M and EBITDA up >16% to $28M, with reaffirmed full-year EBITDA guidance.
likely upward pressure as investors price in strong growth and stable guidance
First report of quarterly numbers shows double‑digit top‑line growth and margin expansion, which typically supports a price rally.
Market effects
Physical therapy sector may see broader optimism as a mid‑cap peer reports strong growth.
U.S. healthcare services segment could receive modest buying interest.
Limited to U.S. healthcare investors; no direct global impact.
Counterpoint
If the reaffirmed guidance is already priced in, the stock may face a short‑term pullback.
Key entities
- companyU.S. Physical Therapy Inc
Provider of outpatient physical therapy services, ticker USPH.
